(Q28346782)

English

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034

scientific article

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034 (English)

0 references

1 reference

1 reference

D Bissett

1

0 references

H L McLeod

series ordinal

2

0 references

B Sheedy

series ordinal

3

0 references

M Collier

series ordinal

4

0 references

Y Pithavala

series ordinal

5

0 references

L Paradiso

series ordinal

6

0 references

M Pitsiladis

series ordinal

7

0 references

J Cassidy

series ordinal

8

0 references

language of work or name

English

0 references

publication date

2 February 2001

0 references

published in

British Journal of Cancer

0 references

volume

84

0 references

issue

3

0 references

page(s)

308-12

0 references

cites work

Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363746

retrieved

29 September 2017

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363746

retrieved

29 September 2017

Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363746

retrieved

29 September 2017

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363746

retrieved

29 September 2017

Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363746

retrieved

29 September 2017

A program package for simulation and parameter estimation in pharmacokinetic systems

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363746

retrieved

2 June 2018

Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363746

retrieved

27 November 2018

Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/11161393

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1054/BJOC.2000.1601

0 references

Dimensions Publication ID

1042784193

0 references

PMC publication ID

2363746

0 references

PubMed publication ID

11161393

0 references

ResearchGate publication ID

12169176

0 references

(Q28346782)

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)